

7. Lu, J. *et al.* MicroRNA expression profiles classify human cancers. *Nature* **435**, 834–838 (2005).
8. Kojima, K. *et al.* MicroRNA122 is a key regulator of α -fetoprotein expression and influences the aggressiveness of hepatocellular carcinoma. *Nat Commun* **2**, 338 (2011).
9. Takata, A. *et al.* MicroRNA-140 acts as a liver tumor suppressor by controlling NF- κ B activity by directly targeting DNA methyltransferase 1 (Dnmt1) expression. *Hepatology* **57**, 162–170 (2013).
10. Trajkovski, M. *et al.* MicroRNAs 103 and 107 regulate insulin sensitivity. *Nature* **474**, 649–653 (2011).
11. Krützfeldt, J. *et al.* Silencing of microRNAs in vivo with 'antagomirs'. *Nature* **438**, 685–689 (2005).
12. Budhraj, A. *et al.* Apigenin induces apoptosis in human leukemia cells and exhibits anti-leukemic activity in vivo. *Mol Cancer Ther* **11**, 132–142 (2012).
13. Shukla, S. *et al.* Blockade of beta-catenin signaling by plant flavonoid apigenin suppresses prostate carcinogenesis in TRAMP mice. *Cancer Res* **67**, 6925–6935 (2007).
14. Wang, W. *et al.* Cell-cycle arrest at G2/M and growth inhibition by apigenin in human colon carcinoma cell lines. *Mol Carcinog* **28**, 102–110 (2000).
15. Paroo, Z., Ye, X., Chen, S. & Liu, Q. Phosphorylation of the human microRNA-generating complex mediates MAPK/Erk signaling. *Cell* **139**, 112–122 (2009).
16. Yi Lau, G. T. & Leung, L. K. The dietary flavonoid apigenin blocks phorbol 12-myristate 13-acetate-induced COX-2 transcriptional activity in breast cell lines. *Food Chem Toxicol* **48**, 3022–3027 (2010).
17. Tatsuta, A. *et al.* Suppression by apigenin of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane in Wistar rats. *Clin Exp Metastasis* **18**, 657–662 (2000).
18. Yin, F., Giuliano, A. E. & Van Herle, A. J. Signal pathways involved in apigenin inhibition of growth and induction of apoptosis of human anaplastic thyroid cancer cells (ARO). *Anticancer Res* **19**, 4297–4303 (1999).
19. Kuo, M. L. & Yang, N. C. Reversion of v-H-ras-transformed NIH 3T3 cells by apigenin through inhibiting mitogen activated protein kinase and its downstream oncogenes. *Biochem Biophys Res Commun* **212**, 767–775 (1995).
20. Yao, S. L. *et al.* Selective radiosensitization of p53-deficient cells by caffeine-mediated activation of p34cdc2 kinase. *Nat Med* **2**, 1140–1143 (1996).
21. Chan, L. P. *et al.* Apigenin induces apoptosis via tumor necrosis factor receptor and Bcl-2-mediated pathway and enhances susceptibility of head and neck squamous cell carcinoma to 5-fluorouracil and cisplatin. *Biochim Biophys Acta* **1820**, 1081–1091 (2012).
22. Mafuvadze, B., Liang, Y., Besch-Williford, C., Zhang, X. & Hyder, S. M. Apigenin induces apoptosis and blocks growth of medroxyprogesterone acetate-dependent BT-474 xenograft tumors. *Horm Cancer* **3**, 160–171 (2012).
23. Nicholas, C. *et al.* Apigenin blocks lipopolysaccharide-induced lethality in vivo and proinflammatory cytokines expression by inactivating NF-kappaB through the suppression of p65 phosphorylation. *J Immunol* **179**, 7121–7127 (2007).
24. Landolfi, R., Mower, R. L. & Steiner, M. Modification of platelet function and arachidonic acid metabolism by bioflavonoids. Structure-activity relations. *Biochem Pharmacol* **33**, 1525–1530 (1984).
25. Hsu, S. H. *et al.* Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. *J Clin Invest* **122**, 2871–2883 (2012).
26. Lanford, R. E. *et al.* Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. *Science* **327**, 198–201 (2010).
27. Elmén, J. *et al.* LNA-mediated microRNA silencing in non-human primates. *Nature* **452**, 896–899 (2008).
28. Esau, C. *et al.* miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. *Cell Metab* **3**, 87–98 (2006).
29. Jopling, C. L., Yi, M., Lancaster, A. M., Lemon, S. M. & Sarnow, P. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. *Science* **309**, 1577–1581 (2005).
30. Lindow, M. & Kauppinen, S. Discovering the first microRNA-targeted drug. *J Cell Biol* **199**, 407–412 (2012).
31. Ku, B. M. *et al.* Caffeine inhibits cell proliferation and regulates PKA/GSK3 β pathways in U87MG human glioma cells. *Mol Cells* **31**, 275–279 (2011).
32. Nishizuka, T. *et al.* Procyanaidins are potent inhibitors of LOX-1: a new player in the French Paradox. *Proc Jpn Acad Ser B Phys Biol Sci* **87**, 104–113 (2011).
33. Teraoka, M. *et al.* Cytoprotective effect of chlorogenic acid against α -synuclein-related toxicity in catecholaminergic PC12 cells. *J Clin Biochem Nutr* **51**, 122–127 (2012).
34. Shukla, S. & Gupta, S. Apigenin: a promising molecule for cancer prevention. *Pharm Res* **27**, 962–978 (2010).
35. Takata, A. *et al.* MicroRNA-22 and microRNA-140 suppress NF- κ B activity by regulating the expression of NF- κ B coactivators. *Biochem Biophys Res Commun* **411**, 826–831 (2011).
36. Kubota, Y., O'Grady, P., Saito, H. & Takekawa, M. Oncogenic Ras abrogates MEK SUMOylation that suppresses the ERK pathway and cell transformation. *Nat Cell Biol* **13**, 282–291 (2011).
37. Suzuki, H. I. *et al.* Modulation of microRNA processing by p53. *Nature* **460**, 529–533 (2009).

Acknowledgments

This work was supported by Grants-in-Aid from the Ministry of Education, Culture, Sports, Science and Technology, Japan (#25293076 and #24390183) (to M. Otsuka and K. Koike), by Health Sciences Research Grants of The Ministry of Health, Labor and Welfare of Japan (to K. Koike), and grants from the Nestlé Nutrition Council, Japan (to A. T.), and the Foundation of All Japan Coffee Association (to M. Otsuka).

Author contributions


M. Ohno, C.S. and M. Otsuka planned the research and wrote the paper. M. Ohno, C.S., T.K., T.Y., A.T., K. Kojima, and M. Otsuka performed the majority of the experiments. M.A. and H.Y. contributed materials. Y.K. supported several experiments. K. Koike supervised the entire project.

Additional information

Supplementary information accompanies this paper at <http://www.nature.com/scientificreports>

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Ohno, M. *et al.* The flavonoid apigenin improves glucose tolerance through inhibition of microRNA maturation in miRNA103 transgenic mice. *Sci. Rep.* **3**, 2553; DOI:10.1038/srep02553 (2013).

 This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported license. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-nd/3.0>

Original Article

Fibrosis score consisting of four serum markers successfully predicts pathological fibrotic stages of chronic hepatitis B

Kenji Ikeda,^{1,2} Namiki Izumi,³ Eiji Tanaka,⁷ Hiroshi Yotsuyanagi,⁴ Yoshihisa Takahashi,⁵ Junichi Fukushima,⁶ Fukuo Kondo,⁵ Toshio Fukusato,⁵ Kazuhiko Koike,⁴ Norio Hayashi⁸ and Hiromitsu Kumada^{1,2}

¹Department of Hepatology, Toranomon Hospital, ²Okinaka Memorial Institute for Medical Research, ³Department of Gastroenterology, Musashino Red Cross Hospital, ⁴Department of Gastroenterology, Tokyo University of Medicine, ⁵Department of Pathology, Teikyo University School of Medicine, ⁶Department of Pathology, NTT Medical Center Tokyo, Tokyo, ⁷Department of Gastroenterology, Shinshu University of Medicine, Matsumoto, and ⁸Department of Gastroenterology, Kansai-Rosai Hospital, Hyogo, Japan

Aim: In order to evaluate and judge a fibrotic stage of patients with chronic hepatitis B, multivariate regression analysis was performed using multiple fibrosis markers.

Method: A total of 227 patients from seven hepatology units and institutes were diagnosed by needle biopsy as having chronic liver disease caused by hepatitis B virus. Twenty-three variables and their natural logarithmic transformation were employed in the multivariate analysis. Multiple regression function was generated from data of 158 patients in one hospital, and validation was performed using the other data of 69 patients from six other hospitals.

Results: After stepwise variable selection, multivariate regression analysis finally obtained the following function: $z = 1.40 \times \ln(\text{type IV collagen 7S}) (\text{ng/mL}) - 0.017 \times (\text{platelet count}) (\times 1000^3/\text{mm}^3) + 1.24 \times \ln(\text{tissue inhibitor of matrix metalloproteinase-2}) (\text{ng/mL}) + 1.19 \times \ln(\alpha\text{-2-macroglobulin})$

(mg/dL) – 9.15. Median values of fibrosis scores of F1 ($n = 73$), F2 ($n = 42$), F3 ($n = 31$) and F4 stages ($n = 12$) were calculated as 0.95, 2.07, 2.98 and 3.63, respectively. Multiple regression coefficient and coefficient of determination were 0.646 and 0.418, respectively. Validation with patient data from other institutions demonstrated good reproducibility of fibrosis score for hepatitis B (FSB), showing 1.33 in F1 ($n = 27$), 2.20 in F2 ($n = 20$), 3.11 in F3 ($n = 20$) and 5.30 in F4 ($n = 2$), respectively.

Conclusion: A concise multiple regression function using four laboratory parameters successfully predicted pathological fibrosis stage of patients with hepatitis B virus infection.

Key words: chronic hepatitis, hepatitis B virus, liver cirrhosis, liver fibrosis, multiple regression analysis, stage

INTRODUCTION

WHEN HEPATITIS B virus (HBV)-related chronic liver disease is found by biochemical and virological examination, liver biopsy can establish the definitive diagnosis of chronic hepatitis and its fibrotic staging. Although these pathological procedures are reliable and informative both in diagnosis and treatment,

they sometimes require medical invasion and financial costs, including the risk of bleeding from needle puncture, some pain experienced during the procedure and hospital stays of a few days. The pathological examination is, therefore, rarely performed repeatedly in a short period of time, unless disease activity is severe or progression of liver disease is highly suspected. Recently, many authors described the usefulness of ultrasonographic elastography and multiple resonance imaging technology in the estimation of staging of chronic hepatitis and cirrhosis.^{1–5} These ways of estimation using the imaging apparatuses seem truly useful for current patients, but they cannot evaluate and compare with past fibrotic states of patients retrospectively. Moreover,

Correspondence: Dr Kenji Ikeda, Department of Hepatology, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo, 105-8470, Japan. Email: ikedakenji@tora.email.ne.jp

Received 6 May 2012; revision 17 September 2012; accepted 4 October 2012.

the same apparatus for elastometry will not be available for repeated measurement for a follow-up examination, for example, several years later.

In spite of the accuracy of biopsy and convenience of elastography in chronic liver disease, clinical diagnosis based on biochemistry and hematology is still indispensable for the daily practice of many patients with HBV-related liver disease. Recently, several studies were published about estimation of hepatitis stages, using one or more serum biomarkers. Discriminant functions or multivariate analyses demonstrated that approximately 60–90% of patients with chronic hepatitis B were correctly classified as having mild hepatitis and severe hepatitis with advanced fibrosis.^{2,6–13} Up to the present time, however, the usefulness of the discriminant functions are less valuable for a few reasons. First, these functions were made for the purpose of discrimination of severe hepatic fibrosis from mild fibrosis, and four histological classifications (F1–F4) were neglected in almost of the studies. Second, some studies analyzed both hepatitis B and hepatitis C virus infection, although the significance and actual values of each liver function test in the evaluation of the severity of liver disease were not similar among each viral hepatitis and alcoholic liver disease. Third, biochemical markers for liver fibrosis (e.g. hyaluronic acid, type IV collagen, procollagen III peptide)^{14–16} were not always included in those previous studies.

We tried to generate a function estimating fibrotic stages of HBV-related chronic hepatitis, which were objectively diagnosed by liver biopsy. The purpose of this study is, therefore, to make a reliable multiple regression function and to obtain practical coefficients for significant variables also using fibrosis markers.

METHODS

Patients

A TOTAL OF 273 Japanese patients with chronic hepatitis B were recruited for the study from seven hospitals in Japan: Toranomon Hospital, Hiroshima University Hospital (K. Chayama, M.D.), Ehime University Hospital (M. Onji, M.D.), Musashino Red Cross Hospital (N. Izumi, MD), Shishu University Hospital (E. Tanaka, M.D.), Showa University Hospital (M. Imawari, M.D.) and Osaka University Hospital (T. Takehara, M.D.). Inclusion criteria for this study were: (i) positive hepatitis B surface antigen for more than 6 months; (ii) persistent or intermittent elevation in aspartate aminotransferase (AST)/alanine aminotransferase (ALT) levels; and (iii) liver biopsy showing chronic hepatitis

(F1–F4). We excluded those patients with overt alcoholic liver disease or fatty liver, association of other types of liver disease (e.g. hepatitis C, primary biliary cirrhosis, autoimmune hepatitis), or those associated with hepatocellular carcinoma or other malignancy. Among the patients, 244 patients fulfilled the conditions for the study: complete demographic data, basic laboratory data of hematology and biochemistry, required liver biopsy specimens, and sufficient amount of frozen sera. Also, we excluded additional 17 patients with eventual histological diagnosis as F0 stage.

Finally, a total of 227 patients who were diagnosed as having chronic hepatitis or cirrhosis (F1–F4) were analyzed for the following hematological, biochemical and histopathological examination. There were 172 males and 55 females aged 16–70 years (median, 39 years).

All the patients presented written informed consent in individual hospitals and medical centers, and the study was approved in each ethical committee.

Hematological and biochemical examination

Hematological and standard biochemical evaluation had been performed in each medical institution: white blood cells, red blood cells, hemoglobin, platelets, total bilirubin, AST, ALT, AST/ALT ratio (AAR), γ -glutamyl transpeptidase (γ -GTP), total protein, albumin and γ -globulin.

Special biochemical examinations including “fibrosis markers” were carried out using stored frozen sera at -20°C or lower: α -2-macroglobulin, haptoglobin concentration, haptoglobin typing, apolipoprotein A1, hyaluronic acid, tissue inhibitor of matrix metalloproteinase (TIMP)-1, TIMP-2, procollagen III peptide and type IV collagen 7S.

Histological diagnosis of chronic hepatitis and cirrhosis

All the 227 cases fulfilled required standards of histological evaluation: sufficient length of specimen, hematoxylin-eosin staining, and at least one specimen with fiber staining. Four independent pathologists (Y. T., J. F., F. K. and T. F.), who were not informed of patients' background and laboratory features except for age and sex, evaluated the 227 specimens regarding the stages of fibrosis and activity. Pathological classification of chronic hepatitis staging was based on Desmet *et al.*¹⁷

Before judgment of histological staging of individual specimens, the pathologists discussed the objective and reproducible judgment of pathological diagnosis of

hepatitis. They made a panel about obvious criteria using typical microscopic pictures for each stage, and it was always referred to during the procedure of pathological judgment. When inconsistent results were found in the diagnosis of hepatitis stage among the pathologists, the final judgment accepted majority rule among them.

Statistical analysis

Non-parametric procedures were employed for the analysis of background characteristics and laboratory data among patients in each stage, including Mann-Whitney *U*-test, Kruskal-Wallis test and χ^2 -test.

The normality of the distribution of the data was evaluated by a Kolmogorov-Smirnov one-sample test. Because certain variables partly did not conform to a normal distribution, natural logarithmic transformation of bilirubin, AST, ALT, γ -GTP, α -2-macroglobulin, hyaluronic acid, type IV collagen 7S and TIMP-2 were also analyzed in the following calculation. The natural logarithmic transformation of the results yielded a normal distribution or symmetrical distribution for all the analyzed factors. After the procedures, the following multiple regression analysis became rationally robust against deviations from normal distribution. In order to avoid introducing into the model any variables that were mutually correlated, we checked the interaction between all pairs of the variables by calculating variance inflation factors. Of the highly correlated variables, less significant factors were removed from the viewpoint of multicollinearity.

Multivariate regression analysis was performed using 158 patient data from Toranomon Hospital (training dataset) to generate a training data of predicting function. We used a stepwise method for selection of informative subsets of explanatory variables in the model. Multiple regression coefficient and coefficient of determination were also taken into account in the selection of variables. Next, we validated the obtained predictive function using the remaining 69 patient data from the other six liver institutions (validation dataset).

A *P*-value of less than 0.05 with two-tailed test was considered to be significant. Data analysis was performed using the computer program SPSS ver. 19.¹⁸

For evaluation of the efficiency and usefulness of obtained function for fibrosis estimation, we compared various fibrosis scores for hepatitis B and C, including AAR,¹⁹ AST-to-platelet ratio index (APRI),²⁰ FIB-4,²¹ FibroTest²² and discrimination function of cirrhosis from hepatitis in Japanese patients.²³

RESULTS

Pathological diagnosis

FOUR PATHOLOGISTS INDEPENDENTLY judged the fibrotic stages and inflammatory activity for 227 specimens of chronic hepatitis/cirrhosis caused by HBV. One hundred patients (44.1%) had a fibrosis stage of F1, 62 (27.3%) F2, 51 (22.5%) F3 and 14 (6.2%) F4. In the subgroup of the 158 patients in the training group, judgment as F1 was made in 73 cases, F2 in 42, F3 in 31 and F4 in 12. Of the 69 patients in the validation group, judgment as F1 was made in 27, F2 in 20, F3 in 20 and F4 in two.

According to hepatitis activity classification, A0 was found in five (2.2%), A1 in 100 (44.1%), A2 in 107 (47.1%) and A3 in 15 (6.6%).

Laboratory data of each hepatitis stage in the training group

There were 124 men and 34 women with a median age of 39 years ranged 16–70 years. Laboratory data of 158 patients in the training group are shown in Table 1. Although several individual items were well correlated with the severity of hepatic fibrosis, significant overlap values were noted among F1–F4 stages: platelet count, γ -globulin, α -2-macroglobulin, haptoglobin, hyaluronic acid, TIMP-2 and type IV collagen 7S.

Significant variables serving staging of hepatitis

Univariate analyses using trend analysis with the Cochran-Armitage method showed that the fibrotic stage of chronic hepatitis B (FSB) was significantly correlated with platelet count (Spearman: $r = -0.45$, $P < 0.001$), γ -GTP ($r = 0.19$, $P = 0.017$), γ -globulin ($r = 0.29$, $P < 0.001$), α -2-macroglobulin ($r = 0.32$, $P < 0.001$), hyaluronic acid ($r = 0.36$, $P < 0.001$), TIMP-2 ($r = 0.16$, $P = 0.043$), procollagen III peptide ($r = 0.30$, $P < 0.001$) and type IV collagen 7S ($r = 0.55$, $P < 0.001$).

Regression function generated from training patient group

After stepwise variable selection, multivariate regression analysis finally obtained the following function: $z = 1.40 \times \ln(\text{type IV collagen 7S (ng/mL)}) - 0.017 \times (\text{platelet count}) (\times 1000^3/\text{mm}^3) + 1.24 \times \ln(\text{TIMP-2 (ng/mL)}) + 1.19 \times \ln(\alpha\text{-2-macroglobulin (mg/dL)}) - 9.15$. Median values of the fibrosis score of F1 ($n = 73$), F2 ($n = 42$), F3 ($n = 31$) and F4 stages ($n = 12$) were calculated as 0.95, 2.07, 2.98 and 3.63, respectively

Table 1 Demography and laboratory data of 158 patients in training group

	F1 (n = 73)	F2 (n = 42)	F3 (n = 31)	F4 (n = 12)
Demographics				
Men : women	58:15	33:9	23:8	10:2
Age (median, range)	36 (16–70)	39.5 (18–66)	39 (25–64)	43 (32–59)
Laboratory data (median, range)				
WBC ($\times 1000/\text{mm}^3$)	5.4 (2.5–10.6)	5.1 (2.4–8.7)	4.9 (3.0–8.7)	4.1 (3.7–6.6)
Hemoglobin (g/dL)	15.3 (10.3–18.8)	15.4 (12.5–17.9)	15.2 (11.5–17.2)	14.45 (12.1–18.2)
Platelet ($\times 1000/\text{mm}^3$)	204 (124–341)	173 (82–308)	155 (96–220)	130 (86–230)
Albumin (g/dL)	4.1 (3.2–4.9)	4.0 (3.2–5.1)	4.0 (3.3–4.9)	3.95 (3.4–4.6)
Bilirubin (mg/dL)	0.8 (0.2–1.7)	0.8 (0.3–2.3)	0.9 (0.4–5.4)	0.85 (0.6–2.3)
AST (IU/L)	48 (16–450)	55 (17–588)	54 (17–1446)	76.5 (27–396)
ALT (IU/L)	102 (10–839)	90 (12–886)	85 (19–2148)	89 (18–809)
γ -GTP (IU/L)	37 (7–247)	55 (8–687)	44 (14–564)	69 (33–262)
γ -Globulin (g/dL)	1.29 (0.78–2.11)	1.495 (0.62–3.20)	1.43 (0.90–2.30)	1.735 (0.92–2.47)
γ -Globulin (%)	17.3 (10.8–26.1)	19.3 (8.5–35.6)	19.9 (12.9–28.6)	22.55 (13.9–30.2)
α -2-Macroglobulin (mg/dL)	226 (116–446)	276 (148–495)	261 (202–565)	286.5 (166–425)
Haptoglobin (mg/dL)	77 (<5–318)	59 (<5–238)	61 (<5–151)	48.5 (<5–145)
Apolipoprotein A-I (mg/dL)	134 (89–212)	143 (78–250)	133 (87–189)	125 (73–169)
Hyaluronic acid ($\mu\text{g/L}$)	16 (<5–130)	32.5 (<5–204)	38 (<5–418)	49 (24–335)
TIMP-1 (ng/mL)	168 (93–271)	172 (116–314)	157 (119–365)	192 (145–365)
TIMP-2 (ng/mL)	80 (41–135)	80.5 (35–121)	92 (38–251)	85.5 (70–123)
Procollagen III peptide (U/mL)	0.75 (0.53–1.90)	0.835 (0.45–1.20)	0.89 (0.58–2.50)	1.05 (0.71–2.20)
Type IV collagen 7S (ng/ml)	4.0 (2.7–7.7)	4.6 (2.6–9.6)	5.6 (2.3–15.0)	7.2 (4.2–14.0)

ALT, alanine aminotransferase; AST, aspartate aminotransferase; γ -GTP, γ -glutamyl transpeptidase; TIMP, tissue inhibitor of matrix metalloproteinase; WBC, white blood cells.

(Fig. 1). The multiple regression coefficient and coefficient of determination were 0.646 ($P < 0.001$) and 0.418 ($P < 0.001$), respectively.

Because the generated regression function was obtained by multivariate analysis with stepwise variable selection, several variables were removed from the function due to multicollinearity among them. Mutual correlation among the fibrosis predictors are shown in Table 2.

A 28-year-old man of F1 fibrotic stage (Fig. 2a) had a serum type IV collagen concentration of 4.4 ng/mL, platelet 221×10^3 count/ mm^3 , TIMP-2 75 ng/mL and α -2-macroglobulin 226 mg/dL. The regression function provided a fibrosis score of 0.99. Another man aged 46 years had F3 fibrosis on histological examination (Fig. 2b). His type IV collagen was 5.3 ng/mL, platelet 137×10^3 count/ mm^3 , TIMP-2 92 ng/mL and α -2-macroglobulin 255, and the regression function calculated his fibrosis score as 3.10.

Validation of discriminant function

Validation data of 69 patients (Table 3) were collected from the other six institutions in Japan. When applying




Figure 1 Box and whisker plots of fibrotic score of each histological fibrosis group in the training dataset. The fibrosis score of hepatitis B was generated by the function, $z = 1.40 \times \ln(\text{type IV collagen 7S}) (\text{ng/mL}) - 0.017 \times (\text{platelet count}) (\times 1000^3/\text{mm}^3) + 1.24 \times \ln(\text{tissue inhibitor of matrix metalloproteinase-2}) (\text{ng/mL}) + 1.19 \times \ln(\alpha\text{-2-macroglobulin}) (\text{mg/dL}) - 9.15$.

Table 2 Correlation coefficients (Spearman's ρ) among fibrosis predictors used in multivariate analysis

	Platelet gamma-globulin	\ln (α -2-macroglobulin)	\ln (hyaluronate)	\ln (P-III-P)	\ln (IV collagen)	\ln (TIMP-2)
Platelet ($\times 10^3/\text{mm}^3$)	1.000	-0.214 ($P = 0.008$)	-0.384 ($P < 0.001$)	-0.045 ($P = 0.58$)	-0.297 ($P < 0.001$)	0.094 ($P = 0.24$)
γ -Globulin (g/dL)	1.000	0.276 ($P = 0.001$)	0.349 ($P < 0.001$)	0.342 ($P < 0.001$)	0.414 ($P < 0.001$)	0.268 ($P = 0.001$)
\ln (α -2-macroglobulin) (mg/dL)	1.000	1.000	0.281 ($P < 0.001$)	0.141 ($P = 0.078$)	0.171 ($P = 0.032$)	-0.079 ($P = 0.32$)
\ln (hyaluronic acid) (mg/L)			1.000	0.373 ($P < 0.001$)	0.493 ($P < 0.001$)	0.089 ($P = 0.27$)
\ln (procollagen III peptide) (IU/mL)				1.000	0.600 ($P < 0.001$)	0.145 ($P = 0.071$)
\ln (type IV collagen) (mg/L)					1.000	0.358 ($P < 0.001$)
\ln (TIMP-2) (mg/L)						1.000

TIMP, tissue inhibitor of matrix metalloproteinase.

the regression function for the validation set, the fibrosis score demonstrated good reproducibility, showing 1.33 in patients with chronic hepatitis of F1 ($n = 27$), 2.20 of F2 ($n = 20$), 3.11 of F3 ($n = 20$) and 5.30 of F4 ($n = 2$), respectively (Fig. 3). Although F4 fibrosis stage consisted of only two patients and the score 5.30 was regarded as of rather higher value, the scores of other stages of fibrosis were concordant with histological fibrosis.

Comparisons of efficacy with various fibrosis scores (Fig. 4)

In order to evaluate the efficacy and usefulness of the obtained FSB, we compared it with previously reported fibrosis scores using training data. AAR, APRI and FibroTest showed only slight correlation with actual histological stage. FIB-4 demonstrated an increasing trend of the score associated with histological fibrosis, but significant overlapping scores were found in F1–F4. Spearman's correlation coefficients of AAR, APRI, FIB-4 and FibroTest were 0.199 ($P = 0.012$), 0.265 ($P = 0.001$), 0.412 ($P < 0.001$) and 0.330 ($P < 0.001$), respectively. Our FSB showed a Spearman's correlation coefficient of 0.625 ($P < 0.001$), and was a much higher value than the others. The dichotomous discrimination function for cirrhosis and hepatitis C in Japanese patients²³ showed good differentiation also in patients with hepatitis B virus.

DISCUSSION

RECOGNITION OF SEVERITY of chronic hepatitis is essential in managing patients with chronic HBV infection: estimation of length of infection, existence of any previous hepatitis activity, presumption of current fibrotic stage, and prediction of future fibrosis progression and hepatocarcinogenesis. Differential diagnosis of cirrhosis from chronic hepatitis is especially important in the evaluation of chronic HBV infection. Identification of liver cirrhosis often leads to an important change in management of the patient: need for fiberoptic examination for esophageal varices, ultrasonographic exploration for the association of liver cancer, and prediction of hepatic decompensation. Guidelines published by the American Association of Study of Liver Disease²⁴ recommend liver biopsy for HBV carriers with aminotransferase elevation or for any candidates of antiviral therapy, because hepatic fibrosis sometimes shows unexpectedly far advancement to cirrhosis, and because it is very difficult to evaluate and translate the liver function tests or ultrasonographic findings compared to chronic hepatitis type C.

Table 3 Demography and laboratory data of 69 patients in training group

	F1 (n = 27)	F2 (n = 20)	F3 (n = 20)	F4 (n = 2)
Demographics				
Men : women	18:9	15:5	13:7	2:0
Age (median, range)	36 (13–64)	45 (14–64)	36.5 (24–59)	32 (25–39)
Laboratory data (median, range)				
WBC ($\times 1000/\text{mm}^3$)	5.0 (2.8–8.7)	5.8 (2.8–11.6)	5.3 (3.2–8.1)	3.85 (2.7–5.0)
Hemoglobin (g/dL)	14.8 (12.4–17.4)	15.0 (12.4–16.9)	14.4 (11.1–16.4)	14.4 (12.5–16.3)
Platelet ($\times 1000/\text{mm}^3$)	204 (86–322)	180 (90–275)	147 (90–276)	130 (67–183)
Albumin (g/dL)	4.4 (2.8–5.2)	4.2 (3.5–5.1)	4.3 (3.4–4.9)	4.45 (4.0–4.9)
Bilirubin (mg/dL)	0.9 (0.4–6.4)	0.8 (0.2–1.6)	0.75 (0.4–1.7)	1.15 (1.1–1.2)
AST (IU/L)	52 (17–575)	50.5 (21–272)	65 (22–284)	248.5 (51–446)
ALT (IU/L)	84 (16–1101)	101.5 (19–554)	86.5 (16–1113)	453.5 (74–833)
γ -GTP (IU/L)	42 (14–332)	54 (16–205)	52.5 (13–191)	193 (57–329)
γ -Globulin (g/dL)	1.30 (1.04–1.59)	1.35 (1.18–2.53)	1.62 (1.16–1.97)	1.545 (1.51–1.58)
γ -Globulin (%)	17.9 (14.3–22.1)	19.6 (15.5–30.8)	22.0 (16.5–24.6)	20.15 (19.3–21.0)
α -2-Macroglobulin (mg/dL)	287 (160–687)	270 (89–452)	272.5 (211–463)	389 (313–465)
Haptoglobin (mg/dL)	58 (<5–229)	74 (<5–154)	56.5 (<5–198)	<5 (<5–<5)
Apolipoprotein A-I (mg/dL)	146 (95–216)	137 (87–162)	120 (88–170)	100.5 (74–127)
Hyaluronic acid ($\mu\text{g/L}$)	27 (<5–113)	36 (10–1050)	59 (14–439)	331 (225–437)
TIMP-1 (ng/mL)	168.5 (83–302)	176 (127–408)	182 (104–303)	390.5 (283–498)
TIMP-2 (ng/mL)	76 (25–143)	86.5 (28–154)	77.5 (32–141)	100.5 (91–110)
Procollagen III peptide (U/mL)	0.71 (0.27–2.20)	0.88 (0.63–2.80)	0.995 (0.60–2.10)	1.75 (1.50–2.00)
Type IV collagen 7S (ng/ml)	3.6 (2.7–17.0)	5.25 (3.3–13.0)	5.7 (3.0–16.0)	15.5 (15.0–16.0)

ALT, alanine aminotransferase; AST, aspartate aminotransferase; γ -GTP, γ -glutamyl transpeptidase; TIMP, tissue inhibitor of matrix metalloproteinase; WBC, white blood cells.

Recently, non-invasive estimation of severity of liver fibrosis has been reported in patients with HBV-related chronic hepatitis.^{2,6–13} However, these studies were principally aimed at differentiation of advanced fibrotic stages of F3 or F4 from mild fibrotic stages of F1 or F2. Those discrimination functions were insufficient to recognize the stepwise progression of viral hepatitis from F1–F4. This dichotomy (mild or severe) of chronic hepatitis B seemed less valuable in the study of disease progression, disease control abilities of antiviral drugs and estimation of histological improvement after anti-inflammatory drugs. A histology-oriented, practical and reliable formula is therefore required for the diagnosis and investigation of chronic hepatitis B.

This study aimed to establish non-invasive evaluation and calculation of liver fibrosis for patients with chronic hepatitis B virus infection. Although it was retrospectively performed as a multicenter study of eight institutions, judgment of histological diagnosis was independently performed by four pathologists in another hospital, who were informed only of the patient's age, sex and positive HBV infection. Objective judgment of the histological staging and grading in sufficient biopsy specimens could be obtained.




Figure 2 Case presentations of the training set. (a) A 28-year-old man with F1 fibrosis. Final regression function provided his fibrosis score as 0.99. (b) A 45-year-old man with F3 fibrosis. His regression coefficient was calculated as 3.10. Silver stain, $\times 40$.




Figure 3 Box and whisker plots of fibrotic score of each group of histological fibrosis in the validation dataset. The fibrosis score of hepatitis B was generated by the function, $z = 1.40 \times \ln(\text{type IV collagen 7S (ng/mL)}) - 0.017 \times (\text{platelet count} \times 1000^3/\text{mm}^3) + 1.24 \times \ln(\text{tissue inhibitor of matrix metalloproteinase-2 (ng/mL)}) + 1.19 \times \ln(\alpha\text{-2-macroglobulin (mg/dL)}) - 9.15$.

As many as 227 patients with chronic hepatitis B were analyzed in this study, who had been diagnosed as having chronic hepatitis or cirrhosis by liver biopsy performed in experienced liver units in Japan. To obtain the most suitable equation approximating histological fibrotic stage, multivariate analysis was performed using two demographic parameters (age and sex) and 21 hematological and biochemical markers with or without logarithmic transformation. They included many kinds of fibrosis markers: α -2-macroglobulin, haptoglobin concentration, haptoglobin typing, apolipoprotein A1, hyaluronic acid, TIMP-1, TIMP-2, procollagen III peptide and type IV collagen 7S. Multiple regression analysis finally generated a first-degree polynomial function consisting of four variables: type IV collagen 7S, platelet count, TIMP-2 and α 2-macroglobulin. A constant numeral (-9.15) was finally adjusted in the regression equation in order to obtain fitted figures for a fibrotic stage of F1–F4. From the magnitude of the standardized partial regression coefficient of individual variable in the function, platelet count demonstrated the most potent contribution toward the prediction of liver fibrosis. Type IV collagen 7S and \ln (TIMP-2) proved to be the second and third distinctive power in the model, respectively.

The FSB was sufficiently fitted to actual fibrotic stages with certain overlapping as is usually found in histological ambiguity judged by pathologists. Because judgment of fibrosis in chronic hepatitis often shows a transitional

histological staging, pathological examination cannot always make a clear-cut diagnosis discriminating F1–F4. Considering the limitation of the pathological difficulty in differentiating the four continuous disease entities, the obtained regression function showed satisfactory high accuracy rates in the prediction of liver disease severity. The FSB can provide one or two decimal places (e.g. 3.2 or 3.24) and the utility of the score is possibly higher than the mere histological stage of F1–F4. The reproducibility was confirmed by the remaining 67 patients' data obtained from the other six hospitals. Although the validation data were collected from a different geographic area and different chronological situation, the FSB showed similar results in prediction of histological staging.

The FSB seemed a very useful quantitative marker in evaluating fibrotic severity of hepatitis B patients without invasive procedures and without any specialized ultrasonography or magnetic resonance imaging. The FSB also has an advantage of measurement, in which old blood samples are available for retrospective assessment of varied clinical settings: for example, old sera from 20 years prior to the time of initial liver biopsy, or paired sera before and after long-term antiviral therapy. These kinds of retrospective assessments of fibrotic staging will be valuable in estimating a long-term progression of liver disease, in evaluating efficacy of long-term medication or other medical intervention, or in making a political judgment from the viewpoints of socioeconomic efficacy.

The score can be calculated for any patients with chronic HBV infection. Although this multiple regression model dealt with appropriate logarithmic transformation for non-normal distribution parameters, the regression analysis was based on a linear regression model. Very slight fibrosis can be calculated as less than 1.00, which is commonly found to a slight degree in chronic hepatitis with tiny fibrotic change as F0. Very severe fibrosis might be calculated as more than 4.00, which is an imaginary and nonsense number in the scoring system of fibrosis. The FSB is, however, very useful and valuable in a real clinical setting: estimation of severity of liver fibrosis in an outpatient clinic, evaluation of the natural progression of a patient's fibrosis over 10 years and assessment of a long-term administration of interferon in patients with chronic hepatitis B from the viewpoint of fibrotic change. Recent development of new nucleoside/nucleotide analogs requires evaluation for long-term histological advantage, for aggravation of hepatitis stage during viral and biochemical breakthrough caused by HBV mutation, and even for




Figure 4 Previously published fibrosis scores. (a) Aspartate aminotransferase/alanine aminotransferase ratio (AAR),¹⁹ (b) aspartate aminotransferase-to-platelet ratio index (APRI),²⁰ (c) FIB-4,²¹ (d) FibroTest²² and (e) discrimination function of cirrhosis from hepatitis in Japanese patients.²³

the best management of patients with chronic hepatitis B. The FSB seems one of the ideal methods of approximating the fibrotic stage of chronic hepatitis B. Repeated measurement is quite suitable for patients with an unestablished treatment or trial, every 1 or 2 years, for example. Because the current regression function was generated from the data of HBV-related chronic liver disease, this equation would not be suitable for the recognition of hepatitis C virus-related chronic liver disease, alcoholic liver disease, and other congenital or

autoimmune liver diseases. To recognize the latter diseases, other studies of individual diseases must be performed.

We compared the usefulness of the FSB with that of other fibrosis scores.¹⁹⁻²³ The more simple and less expensive AAR or APRI could not estimate fibrotic stages with poor correlation coefficients of 0.199 and 0.265, which are much lower than the coefficient of the FSB of 0.625. FibroTest, which contained three costly fibrosis markers (α -2-macroglobulin, haptoglobin and apolipo-

protein A1), also showed a low correlation coefficient of 0.330, suggesting that its usefulness was limited in HBV positive oriental patients. Although FIB-4 demonstrated the best coefficient of 0.412 among the fibrosis scores, significant overlaps were found between neighboring stages and obtained scores were not coordinated for real histological classification.

In conclusion, the FSB was a useful and reliable biomarker for prediction of liver fibrosis in patients with chronic HBV infection. The FSB is expected to be introduced and utilized in varied kinds of studies and trials. Its accuracy and reproducibility require further validation using higher numbers of patients in several countries other than Japan.

ACKNOWLEDGMENTS

THIS STUDY WAS proposed and initiated by Dr Shiro Iino and the project was performed with a grant from the Viral Hepatitis Research Foundation of Japan.

REFERENCES

- Sandrin L, Fourquet B, Hasquenoph JM *et al.* Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. *Ultrasound Med Biol* 2003; 29: 1705–13.
- Myers RP, Tainturier MH, Ratziu V *et al.* Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. *J Hepatol* 2003; 39: 222–30.
- Hanna RF, Kased N, Kwan SW *et al.* Double-contrast MRI for accurate staging of hepatocellular carcinoma in patients with cirrhosis. *AJR Am J Roentgenol* 2008; 190: 47–57.
- Hagiwara M, Rusinek H, Lee VS *et al.* Advanced liver fibrosis: diagnosis with 3D whole-liver perfusion MR imaging—initial experience. *Radiology* 2008; 246: 926–34.
- Taouli B, Chouli M, Martin AJ, Qayyum A, Coakley FV, Vilgrain V. Chronic hepatitis: role of diffusion-weighted imaging and diffusion tensor imaging for the diagnosis of liver fibrosis and inflammation. *J Magn Reson Imaging* 2008; 28: 89–95.
- Montazeri G, Estakhri A, Mohamadnejad M *et al.* Serum hyaluronate as a non-invasive marker of hepatic fibrosis and inflammation in HBeAg-negative chronic hepatitis B. *BMC Gastroenterol* 2005; 5: 32.
- Zeng MD, Lu LG, Mao YM *et al.* Prediction of significant fibrosis in HBeAg-positive patients with chronic hepatitis B by a noninvasive model. *Hepatology* 2005; 42: 1437–45.
- Chrysanthos NV, Papatheodoridis GV, Savvas S *et al.* Aspartate aminotransferase to platelet ratio index for fibrosis evaluation in chronic viral hepatitis. *Eur J Gastroenterol Hepatol* 2006; 18: 389–96.
- Kim BK, Kim Y, Park JY *et al.* Validation of FIB-4 and comparison with other simple noninvasive indices for predicting liver fibrosis and cirrhosis in hepatitis B virus-infected patients. *Liver Int* 2010; 30: 546–53.
- Wu SD, Wang JY, Li L. Staging of liver fibrosis in chronic hepatitis B patients with a composite predictive model: a comparative study. *World J Gastroenterol* 2010; 16: 501–7.
- Sökücü S, Gökçe S, Güllüoğlu M, Aydoğan A, Celtik C, Durmaz O. The role of the non-invasive serum marker FibroTest-ActiTest in the prediction of histological stage of fibrosis and activity in children with naïve chronic hepatitis B infection. *Scand J Infect Dis* 2010; 42: 699–703.
- Liu HB, Zhou JP, Zhang Y, Lv XH, Wang W. Prediction on liver fibrosis using different APRI thresholds when patient age is a categorical marker in patients with chronic hepatitis B. *Clin Chim Acta* 2011; 412: 33–7.
- Park SH, Kim CH, Kim DJ *et al.* Usefulness of Multiple Biomarkers for the Prediction of Significant Fibrosis in Chronic Hepatitis B. *J Clin Gastroenterol* 2011; 45: 361–5.
- Engstrom-Laurent A, Loof L, Nyberg A, Schroder T. Increased serum levels of hyaluronate in liver disease. *Hepatology* 1985; 5: 638–42.
- Murawaki Y, Ikuta Y, Koda M, Kawasaki H. Serum type III procollagen peptide, type IV collagen 7S domain, central triple-helix of type IV collagen and tissue inhibitor of metalloproteinases in patients with chronic viral liver disease: relationship to liver histology. *Hepatology* 1994; 20: 780–7.
- Fabris C, Falletti E, Feferico E, Toniutto P, Pirisi M. A comparison of four serum markers of fibrosis in the diagnosis of cirrhosis. *Ann Clin Biochem* 1997; 34: 151–5.
- Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Sheuer PJ. Classification of chronic hepatitis: diagnosis, grading, and staging. *Hepatology* 1994; 19: 1513–20.
- IBM SPSS Inc. *IBM SPSS for Windows Version 19.0 Manual*. Armonk NY, USA: SPSS Japan Inc., an IBM company, 2009.
- Sheth SG, Flamm SL, Gordon FD *et al.* AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. *Am J Gastroenterol* 1998; 93: 44–8.
- Wai CT, Greenson JK, Fontana RJ *et al.* A simple non-invasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. *Hepatology* 2003; 38: 518–26.
- Sterling RK, Lissen E, Clumeck N *et al.* Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. *Hepatology* 2006; 43: 1317–25.
- Imbert-Bismut F, Ratziu V, Pieroni L *et al.* Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. *Lancet* 2001; 357: 1069–75.
- Ikeda K, Saitoh S, Kobayashi M *et al.* Distinction between chronic hepatitis and liver cirrhosis in patients with hepatitis C virus infection. Practical Discriminant function using common laboratory data. *Hepatol Res* 2000; 18: 252–66.
- Lok ASF, McMahon BJ. AASLD Practice Guidelines. Chronic hepatitis B: update 2009. *Hepatology* 2009; 50: 1–36.

A genome-wide association study of HCV-induced liver cirrhosis in the Japanese population identifies novel susceptibility loci at the MHC region

Yuji Urabe^{1,2}, Hidenori Ochi², Naoya Kato⁴, Vinod Kumar^{1,3}, Atsushi Takahashi³, Ryosuke Muroyama⁴, Naoya Hosono³, Motoyuki Otsuka⁵, Ryosuke Tateishi⁵, Paulisally Hau Yi Lo¹, Chizu Tanikawa¹, Masao Omata⁵, Kazuhiko Koike⁵, Daiki Miki², Hiromi Abe², Naoyuki Kamatani³, Joji Toyota⁶, Hiromitsu Kumada⁷, Michiaki Kubo³, Kazuaki Chayama², Yusuke Nakamura^{1,3}, Koichi Matsuda^{1,*}

¹Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan; ²Department of Medical and Molecular Science, Division of Frontier Medical Science, Programs for Biomedical Research, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan; ³Center for Genomic Medicine, The Institute of Physical and Chemical Research (RIKEN), Kanagawa, Japan; ⁴Unit of Disease Control Genome Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; ⁵Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; ⁶Department of Gastroenterology, Sapporo Kosei General Hospital, Hokkaido, Japan; ⁷Department of Hepatology, Toranomon Hospital, Tokyo, Japan

Background & Aims: We performed a genome-wide association study (GWAS) of hepatitis C virus (HCV)-induced liver cirrhosis (LC) to identify predictive biomarkers for the risk of LC in patients with chronic hepatitis C (CHC).

Methods: A total of 682 HCV-induced LC cases and 1045 CHC patients of Japanese origin were genotyped by Illumina Human Hap 610-Quad bead Chip.

Results: Eight SNPs which showed possible associations ($p < 1.0 \times 10^{-5}$) at the GWAS stage were further genotyped using 936 LC cases and 3809 CHC patients. We found that two SNPs within the major histocompatibility complex (MHC) region on chromosome 6p21, rs910049 and rs3135363, were significantly associated with the progression from CHC to LC ($p_{\text{combined}} = 9.15 \times 10^{-11}$ and 1.45×10^{-10} , odds ratio (OR) = 1.46 and 1.37, respectively). We also found that *HLA-DQA1*0601* and *HLA-DRB1*0405* were associated with the progression from CHC to LC ($p = 4.53 \times 10^{-4}$ and 1.54×10^{-4} with OR = 2.80 and 1.45, respectively). Multiple logistic regression analysis revealed that rs3135363, rs910049, and *HLA-DQA1*0601* were independently associated with the risk of HCV-induced LC. In addition, individ-

uals with four or more risk alleles for these three loci have a 2.83-fold higher risk for LC than those with no risk allele, indicating the cumulative effects of these variations.

Conclusions: Our findings elucidated the crucial roles of multiple genetic variations within the MHC region as prognostic/predictive biomarkers for CHC patients.

© 2013 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Introduction

Two million people in Japan and 210 million people worldwide are estimated to be infected with the hepatitis C virus (HCV), which is known to be a major cause of chronic viral liver disease [1]. Patients with chronic hepatitis C (CHC) usually exhibit mild inflammatory symptoms, but are at a significantly high risk for developing liver cirrhosis (LC) and hepatocellular carcinoma [2]. More than 400,000 people at present suffer from LC, which is ranked as the 9th major cause of death in Japan. In addition, liver cancer causes approximately 32,000 deaths per year, making it the 4th most common cause of death from malignant diseases. Thus, HCV-related diseases are important public health problems [3].

Clinical outcomes after the exposure to HCV vary enormously among individuals. Approximately 70% of infected persons will develop chronic hepatitis [4], and about 20–30% of CHC patients will develop cirrhosis, but others can remain asymptomatic for decades [2]. The annual death rate of patients with decompensated cirrhosis is as high as 15–30% [5]. Moreover, more than 7% of LC patients develop hepatocellular cancer in Japan and Taiwan, while the frequencies are less than 1.6% among other ethnic groups [6,7]. These inter-individual and inter-ethnic differences have been attributed to various factors such as viral genotypes,

Keywords: Genome-wide association study; Hepatitis C virus; Liver cirrhosis; Major histocompatibility complex.

Received 22 April 2012; received in revised form 15 December 2012; accepted 24 December 2012; available online 12 January 2013

* Corresponding author. Address: Laboratory of Molecular Medicine, Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato, Tokyo 108-8639, Japan. Tel.: +81 3 5449 5376; fax: +81 3 5449 5123.

E-mail address: koichima@ims.u-tokyo.ac.jp (K. Matsuda).

Abbreviations: CHC, chronic hepatitis C; GWAS, genome-wide association study; HCV, hepatitis C virus; LC, liver cirrhosis; MHC, major histocompatibility complex; OR, odds ratio; PBC, primary biliary cirrhosis; SNPs, single nucleotide polymorphisms.



ELSEVIER

Research Article

Table 1. Characteristics of samples and methods used in this study.

Stage	Source	Platform	Number of samples	Female (%)	Age, yr (mean ± SD)
GWAS					
Liver cirrhosis	BioBank Japan	Illumina Human Hap 610	682	313 (46.3)	67.1 ± 9.7
Chronic hepatitis C*	Hiroshima University	Illumina Human Hap 610	1045	371 (35.5)	55.2 ± 11.0
Replication					
Liver cirrhosis	Tokyo University	Invader assay	716	334 (46.8)	64.4 ± 10.4
	Hiroshima University		220	98 (44.5)	64.7 ± 8.98
Chronic hepatitis C*	BioBank Japan	Invader assay	1670	780 (46.8)	59.7 ± 12.6
	Hiroshima University		2139	1061 (51.8)	58.8 ± 9.20

*Number of samples that qualified. CHC patients with severe liver fibrosis (F3 or F4) or lower platelet counts (<160,000) were excluded.

alcohol consumption, age at infection, co-infection of HIV or HBV [8–10], insulin resistance, steatosis, and metabolic syndrome [11]. Previous gene expression analyses also identified various genes associated with liver fibrosis among patients with CHC [12–14]. In addition, miRNAs such as mir-21 and mir-122 were shown to be correlated with liver fibrosis [15,16].

Currently, the genome-wide association study is the most common method to identify genetic variations associated with disease risk [17–20]. In addition, the roles of genetic factors in HCV-related diseases have been elucidated. *IL28B* is associated with spontaneous clearance of HCV [21] as well as with the clinical response to the combination therapy of pegylated interferon and ribavirin [22,23]. Recently, our group has shown that SNP rs2596542 on *MICA* [24] and SNP rs1012068 on *DEPDC5* [25] are significantly associated with HCV-induced liver cancer. Although liver cirrhosis is the major risk factor of liver cancer, a fraction of CHC patients will develop HCC without accompanying LC. Therefore, the underlying genetic background would be different between HCV-induced LC and HCV-induced HCC. Previous studies identified the association of genetic variants in *HLA-DQ/DR/B* [26–28], *2-5AS* [29], *TLR3* [30], and *PNPLA3* [31] with the risk of liver fibrosis among patients with CHC. However, a comprehensive approach for HCV-induced LC has not been conducted so far. Here we performed GWAS of HCV-induced LC to identify predictive biomarkers for the risk of LC in patients with CHC.

Materials and methods

Ethics statement

All subjects provided written informed consent. This project was approved by the ethical committees at University of Tokyo, Hiroshima University, Sapporo Kosei General Hospital, Toranomon Hospital, and Center for Genomic Medicine, Institutes of Physical and Chemical Research (RIKEN).

Study population

The characteristics of each cohort are shown in Table 1. In this study, we conducted GWAS and replication analysis on a total of 1618 HCV-induced LC and 4854 CHC patients. All subjects had abnormal levels of serum alanine transaminase for more than 6 months and were positive for both HCV antibody and serum HCV RNA. Among 1618 LC and 4854 CHC samples, 342 LC patients (21.14%) and 2997 CHC patients (61.70%) underwent liver biopsy. The remaining 1276 LC and 1857 CHC patients were diagnosed by non-invasive methods including hepatic imaging (e.g., ultrasonography, computed tomography, arteriography or magnetic resonance imaging), biochemical data (serum bilirubin, serum albumin, platelet, or prothrombin time), and the presence/absence of clinical manifestations of portal hypertension (e.g., varices, encephalopathy or ascites). The patients with CHC

or LC were recruited for this study regardless of their treatment history. We excluded from the analysis the followings CHC patients: (1) advanced liver fibrosis (F3 or F4 by New Inuyama classification) [32], (2) platelet count under 160,000 for patients without liver fibrosis staging, and (3) HBV co-infection. Characteristics of each study cohort are shown in Table 1. In brief, DNA of HCV-induced LC and CHC patients was obtained from Biobank Japan (<http://biobank.jp.org/>) [33], the Hiroshima Liver Study Group (<http://home.hiroshima-u.ac.jp/naika1/researchprofile/pdf/liverstudygroup.pdf>), Toranomon Hospital, and the University of Tokyo. All subjects were of Japanese origin.

SNP genotyping

Genomic DNA was extracted from peripheral blood leukocytes using a standard method. In GWAS, we genotyped 682 LC and 1045 CHC samples using Illumina Human Hap 610-Quad bead Chip (Supplementary Fig. 1). Samples with low call rate (<0.98) were excluded from our analysis (six LC and two CHC samples). We then applied SNP quality control as follows: call rate ≥ 0.99 in LC and CHC samples, Hardy-Weinberg $p \geq 1 \times 10^{-6}$ in LC and CHC samples. Consequently, 461,992 SNPs on the autosomal chromosomes passed the quality control filters. SNPs with minor allele frequency of <0.01 in both LC and CHC samples were excluded from further analyses, considering statistical power in the replication analysis. Finally, we analyzed 431,618 SNPs in GWAS. Among the top ten SNPs showing $p < 1.0 \times 10^{-5}$, we selected nine SNPs for further analysis with LD threshold of $r^2 = 0.95$. In the replication stage, we genotyped 936 LC and 3809 CHC using multiplex PCR-based Invader assay (Third Wave Technologies).

Statistical analysis

The association of SNPs with the phenotype in the GWAS, replication stage, and combined analyses was tested by logistic regression analysis, upon adjusting for age at recruitment (continuous) and gender, by assuming additive model using PLINK [34]. In the GWAS, the genetic inflation factor λ was derived by applying logistic regressed p values for all the tested SNPs. The quantile–quantile plot was drawn using R program. The odds ratios were calculated using the non-susceptible allele as reference, unless stated otherwise. The combined analysis of GWAS and replication stage was verified by using the Mantel-Haenszel method. We set the significance threshold as follows; $p = 1 \times 10^{-5}$ in the GWAS stage (first stage) and $p = 6.25 \times 10^{-3}$ ($=0.05/8$) in the replication analysis. We considered $p < 5 \times 10^{-8}$ as threshold of GWAS significance in the combined analysis, which is the Bonferroni-corrected threshold for the number of independent SNPs genotyped in HapMap Phase II [35]. The heterogeneity across two stages was examined by using the Breslow-Day test [36]. We used Haploview software to analyze the association of haplotypes and LD values between SNPs. Quality control for SNPs was applied as follows: call rate ≥ 0.95 in LC and CHC samples, and Hardy-Weinberg $p \geq 1 \times 10^{-6}$ in CHC samples in replication stage. The statistical power was 19.51% in GWAS (the first stage) ($p = 1.00 \times 10^{-5}$), 97.98% in replication ($p = 0.05/8$), and 74.76% in the combined stage ($p = 5.00 \times 10^{-8}$) at minor allele frequency of 0.3 and OR of 1.3.

Imputation-based association analysis of HLA class I and class II alleles

We obtained an SNP or a combination of SNPs which could tag the HLA alleles in the Japanese population from a previous study [37]. Genotypes of tagging SNPs were imputed in the GWAS samples by using a Hidden Markov model programmed in MACH [38] and haplotype information from HapMap JPT samples




Fig. 1. Regional association plot at 6p21.3. (Upper panel) p Values of genotyped SNPs (circle) and imputed SNPs (cross) are plotted (as $-\log_{10} p$ value) against their physical position on chromosome 6 (NCBI Build 36). The p value for rs910049 at GWAS is represented by a purple diamond. Estimated recombination rates from HapMap JPT show the local LD structure. Inset; the color of the other SNPs indicates LD with rs3135363 according to a scale from $r^2 = 0$ to $r^2 = 1$ based on pair-wise r^2 values from HapMap JPT. (Lower panel) Gene annotations from the University of California Santa Cruz genome browser.

and 1000 genome imputation samples [39]. We applied the same SNP quality criteria as in GWAS, to select SNPs for the analysis. We employed the logistic regression analysis upon age and gender adjustment to assess the associations between HCV-induced LC and HLA alleles.

Software

For general statistical analysis, we employed R statistical environment version 2.9.1 (cran.r-project.org) or plink-1.06 (pngu.mgh.harvard.edu/~purcell/plink/). The Haploview software version 4.2 [40] was used to calculate LD and to draw Manhattan plot. Primer3 -web v0.3.0 (<http://frodo.wi.mit.edu>) web tool was used to design primers. We employed LocusZoom (<http://csg.sph.umich.edu/locuszoom/>) for regional plots. We used SNP Functional Prediction web tool for functional annotation of SNPs (<http://snpinfo.niehs.nih.gov/snpfunc.htm>) [41]. We used "Gene Expression Analysis Based on Imputed Genotypes" (<http://www.sph.umich.edu/csg/liang/imputation>) [42] for eQTL analysis. We used MACTH [43] web tool for searching potential binding sites for transcription factors (<http://www.gene-regulation.com/index.htm>).

Results

Genome-wide association study for HCV-induced liver cirrhosis

We performed a two-stage GWAS using a total of 1618 cases and 4854 controls (Supplementary Fig. 1). In the first stage, a whole genome scan was performed on 682 Japanese patients with HCV-induced LC and 1045 Japanese patients with CHC, using Illumina Human Hap 610-Quad bead Chip. The genotyping results of 431,618 single nucleotide polymorphisms (SNPs) obtained after our standard quality control were used for further analysis.

CHC patients with severe liver fibrosis (F3 or F4 according to the New Inuyama classification [32]) or lower platelet counts ($<160,000$) were excluded from the control group. As progression from CHC to LC is strongly affected by age and gender, we performed logistic regression analyses including age and gender as covariates at all tested loci in our analyses. The genetic inflation factor lambda was 1.051, indicating that there is little or no evidence of population stratification (Supplementary Fig. 2A). Although no SNPs cleared the GWAS significance threshold ($p < 5 \times 10^{-8}$) at the first stage, we selected ten candidate SNPs showing suggestive association of $p < 1 \times 10^{-5}$ (Supplementary Fig. 2B and Supplementary Table 1). After excluding SNP rs6891116 due to almost absolute linkage with SNP rs10252674 ($r^2 = 0.99$), the remaining nine SNPs were further genotyped using an independent cohort, consisting of 936 LC and 3809 CHC cases, by multiplex PCR-based Invader assay as the second stage. We could successfully obtain genotype results for eight SNPs after the QC filter (call rate ≥ 0.95 in LC and CHC samples, Hardy-Weinberg of $p \geq 1 \times 10^{-6}$ in CHC samples). The logistic regression analysis adjusted by age and gender revealed that five SNPs on chromosome 6q21.3 indicated a significant association with progression from CHC to LC after the Bonferroni correction ($p < 0.05/8 = 6.25 \times 10^{-3}$, Supplementary Table 2). A meta-analysis of the two stages with a fixed-effects model revealed that all of the five SNPs significantly associated with progression from CHC to LC (p values of 9.15×10^{-11} – 1.28×10^{-8} with odds ratios (OR) of 1.30–1.46, Fig. 1 and Table 2). These five SNPs were located in the HLA class II region and were in strong linkage disequilibrium with each other (D' > 0.75 ,

Research Article

Table 2. Summary of GWAS and replication analyses.

SNP	Stage	Allele (1/2)	Gene	Liver cirrhosis				Chronic hepatitis C				OR (95% CI) ^b	p value ^c	p value _{het} ^d
				11	12	22	RAF ^a	11	12	22	RAF ^a			
rs910049														
	GWAS	a/g	<i>C6orf10</i>	24	217	435	0.196	25	224	794	0.131	1.73 (1.40-2.15)	5.39 × 10 ⁻⁷	
	Replication		(6p21.3)	38	259	631	0.180	66	952	2790	0.142	1.37 (1.20-1.58)	7.59 × 10 ⁻⁶	
	Combined ^e											1.46 (1.28-1.62)	9.15 × 10 ⁻¹¹	0.075
rs3817963														
	GWAS	a/g	<i>BTNL2</i>	92	343	241	0.390	101	437	505	0.306	1.53 (1.29-1.81)	9.50 × 10 ⁻⁷	
	Replication		(6p21.3)	130	395	395	0.356	409	1573	1816	0.315	1.22 (1.10-1.36)	2.66 × 10 ⁻⁴	
	Combined ^e											1.30 (1.18-1.42)	1.28 × 10 ⁻⁸	0.029
rs9405098														
	GWAS	a/g	No gene	75	293	308	0.328	70	365	608	0.242	1.54 (1.30-1.84)	1.10 × 10 ⁻⁵	
	Replication		(6p21.3)	100	361	462	0.304	249	1429	2129	0.253	1.30 (1.16-1.46)	5.64 × 10 ⁻⁶	
	Combined ^e											1.37 (1.23-1.50)	1.04 × 10 ⁻¹⁰	0.105
rs3135363														
	GWAS	c/t	No gene	35	258	383	0.757	89	447	507	0.700	1.58 (1.32-1.90)	7.89 × 10 ⁻⁷	
	Replication		(6p21.3)	73	322	540	0.750	389	1486	1929	0.702	1.30 (1.16-1.46)	7.94 × 10 ⁻⁶	
	Combined ^e											1.37 (1.24-1.51)	1.45 × 10 ⁻¹⁰	0.069
rs3129860														
	GWAS	a/g	No gene	58	294	324	0.303	57	348	638	0.221	1.55 (1.29-1.82)	6.45 × 10 ⁻⁶	
	Replication		(6p21.3)	88	339	507	0.276	208	1341	2246	0.231	1.28 (1.14-1.44)	2.53 × 10 ⁻⁵	
	Combined ^e											1.36 (1.22-1.49)	1.07 × 10 ⁻⁹	0.085

1618 (682 in GWAS and 936 in replication) liver cirrhosis and 4854 (1045 in GWAS and 3809 in replication) chronic hepatitis C samples were analyzed.

^aRAF, risk allele frequency.

^bOR, odds ratios; CI, confidence interval.

^cp Values obtained by logistic regression analysis adjusted for age and gender under additive model.

^dp Values of heterogeneities (Phet) across three stages were examined by using the Breslow-Day test.

^eCombined odds ratio and p values for independence test were calculated by Mendel-hauzen and Laird method in the meta-analysis.

Supplementary Fig. 3). To further evaluate the effect of each variation on the progression from CHC to LC, we performed multiple logistic regression analyses. As a result, rs910049 (p of 1.91×10^{-3} with OR of 1.25) and rs3135363 (p of 1.49×10^{-4} with OR of 1.23) remained significantly associated with the progression risk from CHC to LC, while the remaining three SNPs failed to show significant associations ($p > 0.05$) (Supplementary Table 3). Thus, two SNPs, rs910049 and rs3135363, seem to be independent risk factors for HCV-induced LC.

Since reduced platelet level is associated with a poor prognosis among CHC patients [44] we excluded patients with platelet level of less than 160,000 from CHC groups to increase the risk of type 2 error in this study. We also conducted the analysis using only CHC patients diagnosed with liver biopsy. As a result, both SNPs reached genome-wide significance ($p < 5 \times 10^{-8}$), although the associations were reduced due to the smaller sample size (Supplementary Table 4).

Subgroup analyses, stratified by IFN treatment status, amount of alcohol consumption, and gender, were also performed, since these factors were shown to be associated with the prognosis of CHC patients [45–47]. A total of 334 LC patients (35.83%) and 2325 CHC (82.4%) were treated with IFN therapy. Although the frequency of IFN treatment was different between CHC and LC groups, these variations associated with the LC risk regardless of IFN treatment as well as gender and alcohol consumption (Supplementary Fig. 4A–C). When we included these factors as covariates, the association of these variations with HCV-induced LC was sustained, with OR of 1.48 and 1.56, and SNP rs3135363

still reached genome-wide significance ($p = 3.95 \times 10^{-9}$) (Supplementary Table 5).

The association of previously reported variations with HCV-induced LC

Non-synonymous SNP rs738409 (I148M) in the *PNPLA3* gene was shown to be associated with progression of LC in the previous prospective study in Caucasians [31]. SNP rs738409 was also associated with the severity of non-alcoholic fatty liver disease in Japanese [48]. Therefore, we analyzed SNP rs738409 in our case-control cohort, but rs738409 did not significantly associate with HCV-induced LC ($p = 0.24$ and OR = 1.10), although the risk G allele was more frequent among LC than CHC (Supplementary Table 6). Our result is similar to what observed among Caucasians in the previous study, in which rs738409 increased liver cancer risk among alcoholic cirrhosis but did not among hepatitis C cirrhosis [49]. Since biological studies demonstrated that its risk allele (G) abolishes the triglyceride hydrolysis activity of *PNPLA3* [50] *PNPLA3* variation would have a strong impact on non-viral cirrhosis.

Recently, GWAS in the Caucasian population identified the association of SNPs rs4374383, rs16851720 and rs9380516 with the progression of liver fibrosis after HCV infection [51]. However, SNPs rs4374383 and rs16851720 did not exhibit significant association ($p = 0.654$ and 0.231 , respectively) in our sample set. Although SNP rs9380516 exhibited the association with p -value of 0.015, the risk allele showed an opposite result

Table 3. Results of three associated variations from candidate gene analyses.

Gene	Tagging SNP	Haplotype frequency		OR (95% CI) ^a		p value ^b
		Liver cirrhosis	Chronic hepatitis C			
<i>DQA1*0601</i>	rs2736182(T) + rs2071293(A)	0.038	0.019	2.80	1.38-3.32	4.53 × 10 ⁻⁴
<i>DRB1*0405</i>	rs411326(C) + rs2395185(A) + rs4599680(A)	0.324	0.266	1.45	1.15-1.56	1.54 × 10 ⁻⁴

Association was tested by comparing haplotype distribution between 682 liver cirrhosis and 1045 chronic hepatitis C samples in GWAS.

^aOR, odds ratio; CI, confidence interval.

^bp Values were obtained by case-control analysis of GWAS stage (p for haplotype were obtained by score test, implemented in R) (*DQA1*0601* and *DRB1*0405*). The p values obtained by logistic regression analysis adjusted for age and gender under additive model.

(Supplementary Table 6). Taken together, these SNPs would not be associated with liver fibrosis in the Japanese population.

Genes related to extracellular matrix turnover or immune response (*KRT 19*, *COL1A1*, *STMN2*, *CXCL6*, *CCR2*, *TIMP1*, *IL8*, *IL1A*, *ITGA2*, *CLDN 4*, and *IL2*) were shown to be implicated in liver fibrosis of chronic hepatitis C [14]. To further characterize these loci, we conducted imputation analyses in the GWAS sample set (682 cases and 1045 controls), using data from HAPMAP phase II (JPT), and found 163 SNPs in 9 loci. However, none of these SNPs indicated significant association with p-value of less than 0.01 (Supplementary Table 7). Thus, variations of these genes did not associate with progression from chronic hepatitis C to liver cirrhosis.

Imputation-based fine mapping of HLA region

The most significantly associated SNP rs3135363 is located within an intergenic region between *BTNL2* and *HLA-DRA*, and rs910049 is located in intron 7 of *C6orf10* gene (Supplementary Figs. 5 and 6). To further characterize these loci, we conducted imputation-based association analysis for the GWAS samples (682 LC and 1045 CHC samples) using data from HAPMAP Phase II (JPT), and could obtain the results of nearly 6000 SNPs in a 4-Mb genomic region. The regional association plots revealed that all modestly-associated SNPs are confined within a 700-kb region containing 21 genes, namely *TNXB*, *ATF6B*, *FKBPL*, *PRRT1*, *PPT2*, *EGFL8*, *AGPAT1*, *RNF5*, *RNF5P1*, *AGER*, *PBX2*, *C6orf10*, *BTNL2*, *HLA-DRA*, *HLA-DRB5*, *HLA-DRB6*, *HLA-DRB1*, *HLA-DQA1*, *HLA-DQA2*, *HLA-DQB1* and *HLA-DQB2* (Supplementary Fig. 5). Although 640 SNPs, including ten non-synonymous SNPs within the 4-Mb region, showed very modest associations ($p < 0.01$) with HCV-induced LC, none of these SNPs in this region revealed strong association with HCV-induced LC, after adjustment with the two SNPs, rs910049 and rs3135363 (Supplementary Fig. 7). Taken together, the associations observed in this region would reflect the association with rs910049 and rs3135363.

Previous reports indicated the association of *HLA-DRB1* and *HLA-DQ* alleles with HCV-induced chronic hepatitis in the Japanese population [26]. To investigate the association of HLA alleles with HCV-induced LC, we estimated the genotypes at the HLA region by applying the imputation results of HLA-tagging SNPs [37]. We could successfully determine 53 alleles of *HLA-A*, *B*, *C*, *DQA*, *DQB*, and *DRB* genes and find that *HLA-DQA1*0601* and *HLA-DRB1*0405* were strongly associated with HCV-induced LC (p values of 4.53×10^{-4} and 1.54×10^{-4} with ORs of 2.80 and 1.45) even after the Bonferroni correction ($p < 0.05/53 = 9.43 \times 10^{-4}$) (Table 3 and Supplementary Table 8A-E) [37].




Fig. 2. Cumulative effects of liver cirrhosis risk alleles. (A) Frequency distribution divided by risk allele numbers (rs910049, rs3135353, and *HLA-DQA0601*) among liver cirrhosis (light blue bars) and chronic hepatitis C (dark blue bars) patients. (B) Plot of the increase odds ratio (OR) for liver cirrhosis according to the number of risk alleles. The ORs are relative to the subjects with no risk alleles (rs910049, rs3135353, and *HLA-DQA0601*). Vertical bars correspond to 95% confidence intervals. Horizontal line marks the null value (OR = 1).

Cumulative effect of multiple loci within the HLA region

SNPs rs3135363 and rs910049, *HLA-DQA1*0601*, and *HLA-DRB1*0405* are located within a 300-kb segment in the HLA class II region and show moderate linkage disequilibrium (Supplementary Fig. 8). To further evaluate these genetic factors, we performed multiple logistic regression analyses and found that rs910049 (p of 9.40×10^{-3} with OR of 1.38), rs3135363 (p of 3.94×10^{-4} with OR = 1.41), and *HLA-DQA1*0601* (p of 7.79×10^{-3} with OR of 1.54) were significantly associated with HCV-induced LC (Supplementary Table 9), indicating these three variations were independent risk factors for progression of CHC to LC.

To investigate the pathophysiological roles of rs910049 and rs3135363 in disease progression, we searched the eQTL database (<http://www.sph.umich.edu/csg/liang/imputation>) and found that risk alleles of rs910049 (A) and rs3135363 (T) were associated with lower expression of *HLA-DQA* (LOD of ≥ 6.86 and 17.31, respectively) and *DRB1* (LOD of ≥ 12.01 and 18.96, respectively), and with higher expression of *HLA-DQB1* (LOD of ≥ 6.76 and 4.46, respectively) (Supplementary Table 10). Thus, rs910049 and rs3135363 are likely to affect the expression of HLA class II molecules and subsequently alter the risk of HCV-induced LC.

Finally, we examined the cumulative effects of rs910049, rs3135363, and *HLA-DQA1*0601*. Individuals with four or more risk alleles (8.8% of general population) have 2.83-fold higher risk of HCV-induced LC compared with those with no risk allele (15.0% of general population, Fig. 2).

Research Article

Discussion

We here demonstrated that multiple genetic variations in the MHC region were significantly associated with the risk of disease progression from CHC to LC, using a total of 1618 HCV-LC and 4854 CHC cases. Since a substantial proportion of patients with CHC show progression to LC in a certain time period, exclusion of CHC patients who have a high risk for LC from control subjects is essential to reduce the risk of false negative association. In this study, CHC patients with advanced fibrosis (F3 or F4 in stage) or with reduced platelet level (less than 160,000/ μ l) were excluded from the control samples, since these alterations are well-known risk factors for LC development [9,32]. Consequently, we were successfully able to identify the HCV-induced LC loci.

HLA genes are known to play critical roles in the regulation of our immune responses through controlling the antigen presentation to CD8 (class I) and CD4 (class II) T cells. Although previous studies indicated the association of HLA class I alleles such as *HLA-B57*, *HLA-A11*, and *HLA-C04* with persistent HCV infection [52,53], no SNPs in the HLA class I region exhibited strong association with HCV-induced LC. Here we identified three variations (rs910049, rs3135363, *HLA-DQA1*0601*) in the HLA class II region to be significantly associated with the progression risk from CHC to LC. Since two SNPs, rs910049 and rs3135363, had been indicated to affect expression levels of *HLA-DRB1* and *DQ*, our findings indicated the significant pathophysiological roles of HLA class II molecules in the development of HCV-induced liver fibrosis. Considering the function of *HLA-DQ* and *HLA-DR*, we suggest that the antigen presentation by HLA class II molecules is likely to play a critical role in the elimination of HCV-infected liver cells and subsequently prevent HCV-induced LC.

Direct acting antiviral drugs for HCV can cure up to 75% of patients infected with HCV genotype 1, and the lifetime risk of developing LC and HCC among HCV carriers was decreased during the two recent decades [54,13]. However, the amino acid sequence of the NS3 protease domain varies significantly between HCV genotypes and the antiviral efficacy differs in different HCV genotypes [55]. Moreover, protease inhibitors increased the incidence of adverse reactions such as anemia and skin rash [56]. Therefore, estimation of liver cirrhosis risk and prediction of treatment response would be essential to provide a personalized treatment and to achieve the optimal results. Due to the recent advances in pharmacogenetic studies, genetic factors associated with efficacy and adverse effects of anti-HCV treatment were identified. *IL-28B* is a powerful predictor of treatment outcome of pegylated interferon and ribavirin therapy [22], while a genetic variation in the *ITPA* gene was shown to be associated with ribavirin-induced anemia [57]. Since we conducted a retrospective study, and the majority of LC patients did not receive IFN treatment, we could not evaluate the treatment responses in our study design. However, SNPs identified in this study were associated with the LC risk independent of IFN treatment. Although the impact of each SNP was relatively weak compared with viral factors (HCV genotype, core and NS5A mutation [58]) and host factors (age, gender, obesity, and insulin resistance), we found that individuals with three or more risk alleles have a nearly three-fold higher risk of LC than those with no risk allele. Since lifetime risk of HCC development among HCV carriers is as high as about 27% for male and 8% for female [59], these three loci would have the strong effect on the clinical outcome of CHC patients. In general, the progression from chronic hepatitis C to liver cirrhosis usually takes more than 20–30 years. Therefore,

a large scale prospective cohort study with more than 10-year follow-up is essential to evaluate the role of these variations as a prognostic biomarker. We would like to perform prospective analysis in future studies. We hope that our findings would contribute to clarify the underlying molecular mechanism of HCV-induced liver cirrhosis.

Financial support

This work was conducted as a part of the BioBank Japan Project that was supported by the Ministry of Education, Culture, Sports, Science and Technology of the Japanese government.

Conflict of interest

The authors who have taken part in this study declared that they do not have anything to disclose regarding funding or conflict of interest with respect to this manuscript.

Authors' contributions

Y. U., K. K., K. C., and K.M. conceived and designed the study; Y. U., H. O., N. K., Y. K., R. M., N. H., and M. K. performed genotyping; A. T., P. H. Y. L., C. T., and N. K. performed quality control at genome-wide phase; M. O., R. T., M. O., K. K., D. M., H. A., J. T., H. K., Y. N., K. M. and M. K. managed DNA samples; Y. U. analyzed and summarized the whole results; Y. U., Y. N., and K. M. wrote the manuscript; Y. N. obtained funding for the study.

Acknowledgments

We thank Ayako Matsui and Hiroe Tagaya (the University of Tokyo), and the technical staff of the Laboratory for Genotyping Development, Center for Genomic Medicine, RIKEN, for their technical support.

Supplementary data

Supplementary data associated with this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.jhep.2012.12.024>.

References

- [1] Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. *Lancet Infect Dis* 2005;5:558–567.
- [2] Seeff LB. Natural history of chronic hepatitis C. *Hepatology* 2002;36:S35–S46.
- [3] Thomas DL, Seeff LB. Natural history of hepatitis C. *Clin Liver Dis* 2005;9:383–398, vi.
- [4] Freeman AJ, Dore GJ, Law MG, Thorpe M, Von Overbeck J, Lloyd AR, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. *Hepatology* 2001;34:809–816.
- [5] Hoofnagle JH. Hepatitis C: the clinical spectrum of disease. *Hepatology* 1997;26:15S–20S.
- [6] Tanaka H, Imai Y, Hiramatsu N, Ito Y, Imanaka K, Oshita M, et al. Declining incidence of hepatocellular carcinoma in Osaka, Japan, from 1990 to 2003. *Ann Intern Med* 2008;148:820–826.

- [7] Global burden of disease (GBD) for hepatitis C. *J Clin Pharmacol* 2004;44:20–29.
- [8] Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. *Lancet* 1997;349:825–832.
- [9] Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of hepatocarcinogenesis by interferon therapy. *Ann Intern Med* 1999;131:174–181.
- [10] Zhang Q, Tanaka K, Sun P, Nakata M, Yamamoto R, Sakimura K, et al. Suppression of synaptic plasticity by cerebrospinal fluid from anti-NMDA receptor encephalitis patients. *Neurobiol Dis* 2012;45:610–615.
- [11] Aghemo A, Prati GM, Rumi MG, Soffredini R, D'Ambrosio R, Orsi E, et al. A sustained virological response prevents development of insulin resistance in chronic hepatitis C patients. *Hepatology* 2012;56:549–556.
- [12] Bièche I, Asselah T, Laurendeau I, Vidaud D, Degot C, Paradis V, et al. Molecular profiling of early stage liver fibrosis in patients with chronic hepatitis C virus infection. *Virology* 2005;332:130–144.
- [13] Estrabaud E, Vidaud M, Marcellin P, Asselah T. Genomics and HCV infection: progression of fibrosis and treatment response. *J Hepatol* 2012;57:1110–1125.
- [14] Asselah T, Bièche I, Laurendeau I, Paradis V, Vidaud D, Degot C, et al. Liver gene expression signature of mild fibrosis in patients with chronic hepatitis C. *Gastroenterology* 2005;129:2064–2075.
- [15] Marquez RT, Bandyopadhyay S, Wendlandt EB, Keck K, Hoffer BA, Icardi MS, et al. Correlation between microRNA expression levels and clinical parameters associated with chronic hepatitis C viral infection in humans. *Lab Invest* 2010;90:1727–1736.
- [16] Morita K, Taketomi A, Shirabe K, Umeda K, Kayashima H, Ninomiya M, et al. Clinical significance and potential of hepatic microRNA-122 expression in hepatitis C. *Liver Int* 2011;31:474–484.
- [17] Cui R, Okada Y, Jang SG, Ku JL, Park JG, Kamatani Y, et al. Common variant in 6q26-q27 is associated with distal colon cancer in an Asian population. *Gut* 2011;60:799–805.
- [18] Kumar V, Matsuo K, Takahashi A, Hosono N, Tsunoda T, Kamatani N, et al. Common variants on 14q32 and 13q12 are associated with DLBC susceptibility. *J Hum Genet* 2011;56:436–439.
- [19] Tanikawa C, Urabe Y, Matsuo K, Kubo M, Takahashi A, Ito H, et al. A genome-wide association study identifies two susceptibility loci for duodenal ulcer in the Japanese population. *Nat Genet* 2012;44:430–434.
- [20] Urabe Y, Tanikawa C, Takahashi A, Okada Y, Morizono T, Tsunoda T, et al. A genome-wide association study of nephrolithiasis in the Japanese population identifies novel susceptible loci at 5q35.3, 7p14.3, and 13q14.1. *PLoS Genet* 2012;8:e1002541.
- [21] Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. *Nature* 2009;461:798–801.
- [22] Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. *Nat Genet* 2009;41:1105–1109.
- [23] Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. *Nat Genet* 2009;41:1100–1104.
- [24] Kumar V, Kato N, Urabe Y, Takahashi A, Muroyama R, Hosono N, et al. Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma. *Nat Genet* 2011;43:455–458.
- [25] Miki D, Ochi H, Hayes CN, Abe H, Yoshima T, Aikata H, et al. Variation in the DEPDC5 locus is associated with progression to hepatocellular carcinoma in chronic hepatitis C virus carriers. *Nat Genet* 2011;43:797–800.
- [26] Kuzushita N, Hayashi N, Moribe T, Katayama K, Kanto T, Nakatani S, et al. Influence of HLA haplotypes on the clinical courses of individuals infected with hepatitis C virus. *Hepatology* 1998;27:240–244.
- [27] Singh R, Kaul R, Kaul A, Khan K. A comparative review of HLA associations with hepatitis B and C viral infections across global populations. *World J Gastroenterol* 2007;13:1770–1787.
- [28] Mosaad YM, Farag RE, Arafa MM, Eletreby S, El-Alfy HA, Eldeek BS, et al. Association of human leucocyte antigen Class I (HLA-A and HLA-B) with chronic hepatitis C virus infection in Egyptian patients. *Scand J Immunol* 2010;72:548–553.
- [29] Li CZ, Kato N, Chang JH, Muroyama R, Shao RX, Dharel N, et al. Polymorphism of OAS-1 determines liver fibrosis progression in hepatitis C by reduced ability to inhibit viral replication. *Liver Int* 2009;29:1413–1421.
- [30] Mozer-Lisewska I, Sikora J, Kowala-Piaskowska A, Kaczmarek M, Dworacki G, Zeromski J. The incidence and significance of pattern-recognition receptors in chronic viral hepatitis types B and C in man. *Arch Immunol Ther Exp (Warsz)* 2010;58:295–302.
- [31] Trépo E, Pradat P, Potthoff A, Momozawa Y, Quertinmont E, Gustot T, et al. Impact of patatin-like phospholipase-3 (rs738409 C>G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C. *Hepatology* 2011;54:60–69.
- [32] Romero-Gómez M, Gómez-González E, Madrazo A, Vera-Valencia M, Rodrigo L, Pérez-Alvarez R, et al. Optical analysis of computed tomography images of the liver predicts fibrosis stage and distribution in chronic hepatitis C. *Hepatology* 2008;47:810–816.
- [33] Nakamura Y. The BioBank Japan project. *Clin Adv Hematol Oncol* 2007;5:696–697.
- [34] Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira M, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet* 2007;81:559–575.
- [35] Frazer KA, Ballinger DG, Cox DR, Hinds DA, Stuve LL, Gibbs RA, et al. A second generation human haplotype map of over 3.1 million SNPs. *Nature* 2007;449:851–861.
- [36] Breslow NE, Day NE. Statistical methods in cancer research. The design and analysis of cohort studies. *IARC Sci Publ* 1987;11:1–406.
- [37] de Bakker PI, McVean G, Sabeti PC, Miretti MM, Green T, Marchini J, et al. A high-resolution HLA and SNP haplotype map for disease association studies in the extended human MHC. *Nat Genet* 2006;38:1166–1172.
- [38] Scott LJ, Mohlke KL, Bonnycastle LL, Willer CJ, Li Y, Duren WL, et al. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. *Science* 2007;316:1341–1345.
- [39] Consortium GP. A map of human genome variation from population-scale sequencing. *Nature* 2010;467:1061–1073.
- [40] Barrett J, Fry B, Maller J, Daly M. Haploview: analysis and visualization of LD and haplotype maps. *Bioinformatics* 2005;21:263–265.
- [41] Xu Z, Taylor JA. SNPinfo: integrating GWAS and candidate gene information into functional SNP selection for genetic association studies. *Nucleic Acids Res* 2009;37:W600–W605.
- [42] Dixon AL, Liang L, Moffatt MF, Chen W, Heath S, Wong KC, et al. A genome-wide association study of global gene expression. *Nat Genet* 2007;39:1202–1207.
- [43] Kel AE, Gössling E, Reuter I, Chermushkin E, Kel-Margoulis OV, Wingender E. MATCH: a tool for searching transcription factor binding sites in DNA sequences. *Nucleic Acids Res* 2003;31:3576–3579.
- [44] Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. *Hepatology* 2003;38:518–526.
- [45] Cammà C, Di Bona D, Schepis F, Heathcote EJ, Zeuzem S, Poockros PJ, et al. Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data. *Hepatology* 2004;39:333–342.
- [46] Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. *Hepatology* 2002;36:S47–S56.
- [47] Silini E, Bottelli R, Asti M, Bruno S, Candusso ME, Brambilla S, et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a case-control study. *Gastroenterology* 1996;111:199–205.
- [48] Kawaguchi T, Sumida Y, Umemura A, Matsuo K, Takahashi M, Takamura T, et al. Genetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non-alcoholic fatty liver disease in Japanese. *PLoS One* 2012;7:e38322.
- [49] Nischalke HD, Berger C, Luda C, Berg T, Müller T, Grünhage F, et al. The PNPLA3 rs738409 148M/M genotype is a risk factor for liver cancer in alcoholic cirrhosis but shows no or weak association in hepatitis C cirrhosis. *PLoS One* 2011;6:e27087.
- [50] He S, McPhaul C, Li JZ, Garuti R, Kinch L, Grishin NV, et al. A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. *J Biol Chem* 2010;285:6706.
- [51] Patin E, Kutalik Z, Guernon J, Bibert S, Nalpas B, Jouanguy E, et al. Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection. *Gastroenterology* 2012;143:124–152, e1–12.
- [52] Kim AY, Kuntzen T, Timm J, Nolan BE, Baca MA, Reyor LL, et al. Spontaneous control of HCV is associated with expression of HLA-B 57 and preservation of targeted epitopes. *Gastroenterology* 2011;140:e681.
- [53] Fanning LJ, Kenny-Walsh E, Shanahan F. Persistence of hepatitis C virus in a white population: associations with human leukocyte antigen class 1. *Hum Immunol* 2004;65:745–751.

Research Article

- [54] Imhof I, Simmonds P. Genotype differences in susceptibility and resistance development of hepatitis C virus to protease inhibitors telaprevir (VX-950) and danoprevir (ITMN-191). *Hepatology* 2011;53:1090-1099.
- [55] Asselah T, Marcellin P. Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow. *Liver Int* 2012;32:88-102.
- [56] Ozeki I, Akaike J, Karino Y, Arakawa T, Kuwata Y, Ohmura T, et al. Antiviral effects of peginterferon alpha-2b and ribavirin following 24-week monotherapy of telaprevir in Japanese hepatitis C patients. *J Gastroenterol* 2011;46:929-937.
- [57] Ochi H, Maekawa T, Abe H, Hayashida Y, Nakano R, Kubo M, et al. ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy - a genome-wide study of Japanese HCV virus patients. *Gastroenterology* 2010;139:1190-1197.
- [58] Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. *N Engl J Med* 1996;334:77-82.
- [59] Huang YT, Jen CL, Yang HI, Lee MH, Su J, Lu SN, et al. Lifetime risk and sex difference of hepatocellular carcinoma among patients with chronic hepatitis B and C. *J Clin Oncol* 2011;29:3643-3650.

Perihepatic lymph node enlargement is a negative predictor of liver cancer development in chronic hepatitis C patients

Hiromi Hikita · Hayato Nakagawa · Ryosuke Tateishi · Ryota Masuzaki · Kenichiro Enooku · Haruhiko Yoshida · Masao Omata · Yoko Soroida · Mamiko Sato · Hiroaki Gotoh · Atsushi Suzuki · Tomomi Iwai · Hiromitsu Yokota · Kazuhiko Koike · Yutaka Yatomi · Hitoshi Ikeda

Received: 5 January 2012 / Accepted: 19 June 2012 / Published online: 12 July 2012
© Springer 2012

Abstract

Background Perihepatic lymph node enlargement (PLNE) is a common ultrasound finding in chronic hepatitis C patients. Although PLNE is considered to reflect the inflammatory response to hepatitis C virus (HCV), its clinical significance remains unclear.

Methods Between December 2004 and June 2005, we enrolled 846 chronic hepatitis C patients in whom adequate ultrasound examinations had been performed. PLNE was defined as a perihepatic lymph node that was at least 1 cm in the longest axis by ultrasonography. We analyzed the clinical features of patients with PLNE and prospectively investigated the association between PLNE and hepatocellular carcinoma (HCC) development.

Results We detected PLNE in 169 (20.0 %) patients. Female sex, lower body mass index (BMI), and HCV serotype 1 were independently associated with the presence of

PLNE. However, there were no significant differences in liver function tests, liver stiffness, and hepatitis C viral loads between patients with and without PLNE. During the follow-up period (mean 4.8 years), HCC developed in 121 patients. Unexpectedly, patients with PLNE revealed a significantly lower risk of HCC development than those without PLNE ($p = 0.019$, log rank test). Multivariate analysis revealed that the presence of PLNE was an independent negative predictor of HCC development (hazard ratio 0.551, $p = 0.042$). In addition, the sustained viral response rate in patients who received interferon (IFN) therapy was significantly lower in patients with PLNE than in patients without PLNE.

Conclusions Patients with PLNE had a lower risk of HCC development than those without PLNE. This study may provide new insights into daily clinical practice and the pathophysiology of HCV-induced hepatitis and hepatocarcinogenesis.

Keywords Perihepatic lymph node enlargement · Chronic hepatitis C · Hepatocarcinogenesis

H. Hikita and H. Nakagawa contributed equally to this work.

H. Hikita · H. Nakagawa · K. Enooku · Y. Soroida · M. Sato · H. Gotoh · A. Suzuki · T. Iwai · H. Yokota · Y. Yatomi · H. Ikeda

Department of Clinical Laboratory Medicine,
Graduate School of Medicine, University of Tokyo,
7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan

H. Nakagawa (✉) · R. Tateishi · R. Masuzaki · K. Enooku · H. Yoshida · K. Koike · H. Ikeda

Department of Gastroenterology, Graduate School of Medicine,
University of Tokyo, 7-3-1 Hongo, Bunkyo-ku,
Tokyo 113-8655, Japan
e-mail: n-hayato@yf7.so-net.ne.jp

M. Omata
Yamanashi Prefectural Hospital Organization,
1-1-1 Fujimi, Kofu, Yamanashi 400-8506, Japan

Abbreviations

ALT	Alanine aminotransferase
AFP	α -Fetoprotein
PLNE	Perihepatic lymph node enlargement
HCV	Hepatitis C virus
HCC	Hepatocellular carcinoma
IFN	Interferon
LN	Lymph node
US	Ultrasonography

Introduction

Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and chronic hepatitis C virus (HCV)

infection is a major cause of HCC in the United States, southern European countries, and Japan [1, 2]. The host immune responses to HCV are often not strong enough to completely clear the infection, resulting in chronic stimulation of the antigen-specific immune response. Accumulating basic and clinical lines of evidence indicate that a sustained inflammatory reaction in the liver is the major contributing factor to HCC development [3–5].

Inflammatory processes in organs frequently lead to hyperplasia of regional lymph nodes (LNs). Perihepatic LN enlargement (PLNE) is a common finding in patients with chronic hepatitis, especially in patients with hepatitis C [6, 7]. Some studies have revealed that PLNE in chronic hepatitis C patients was associated with a higher HCV viral load, [7] higher histological grade of hepatic inflammation and fibrosis [8, 9], and higher CD8 lymphocyte level in the blood [10]; therefore, PLNE is considered to reflect an inflammatory response to HCV. However, such associations as those noted above are inconsistent among studies [7–15], and the precise mechanism and clinical relevance of PLNE are not fully understood. Furthermore, to our knowledge, there have been no studies designed to investigate the association between PLNE and hepatocarcinogenesis. To clarify whether we should pay attention to the risk of HCC development in patients with PLNE is very important, because we encounter such situations very often.

The purpose of this study was to reevaluate the clinical relevance of PLNE and to carry out a prospective assessment of the association between PLNE and HCC development. To elucidate these matters, we investigated a well-characterized chronic hepatitis C cohort in which we previously reported the utility of performing transient elastography for risk assessment of HCC development [16]. In the present study, we prospectively assessed the association between PLNE and HCC development in chronic hepatitis C patients in that cohort.

Patients and methods

Patients and screening for perihepatic LN enlargement

As described previously [16], we enrolled 866 chronic hepatitis C patients, excluding those with HCC or a past history of it, who visited the University of Tokyo Hospital between December 2004 and June 2005. All patients were positive for HCV-RNA and showed at least a transiently elevated serum alanine aminotransferase (ALT) level. Patients with concomitant hepatitis B virus surface antigen positivity, patients with uncontrollable ascites, patients on interferon (IFN) therapy, and patients who visited only for consultation purposes were excluded from this study.

Each subject was screened for HCC with ultrasonography (US) at or immediately after the first visit. At the same time, we surveyed the presence of PLNE with US. The US examination was performed using the SSD-2000 (Aloka, Tokyo, Japan). To identify LNs the following criteria were used, according to a previous report [17]: one or more masses with an ovoid shape and less echogenic than liver parenchyma, separated from adjacent organs and vessels by a clear-cut cleavage on repeated transverse, sagittal, and oblique scans. LNs were searched for near the trunk of the portal vein, hepatic artery, celiac axis, superior mesenteric vein, and pancreas head. Furthermore, we used Doppler US to differentiate LNs from vessels.

We defined PLNE as an LN that was at least 1 cm in the longest axis. There were two reasons for this definition. First, we preliminarily investigated the prevalence of PLNE with US in 465 healthy subjects who had had medical check-ups and did not have liver disease or other underlying causes of LN enlargement. We found that only 15 (3.2 %) of these subjects had a perihepatic LN larger than 1 cm in the longest axis (unpublished data). Second, when an LN was smaller than 1 cm, it was sometimes difficult to distinguish the LN from other structures. If two or more LNs were detected with US, we determined PLNE to be present based on the length of the largest LN. In 20 of the 866 patients in the present study, adequate visualization of the liver hilum was not achieved with US because of severe obesity or excessive meteorism. Therefore, we analyzed the association between PLNE and the subsequent incidence of HCC in 846 patients.

HCV RNA was measured using Amplicore HCV version 2.0 (Roche, Tokyo, Japan), and the HCV serotype was examined using a serotyping assay (SRL, Tokyo, Japan). We also monitored IFN therapy and responses during the follow-up period. A sustained virological response (SVR) was defined as undetectable HCV-RNA at least 24 weeks after the end of therapy. All blood tests were performed at the time of US examination.

The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki.

Patient follow up

Patients were followed up every 3–6 months at the outpatient clinic, when blood tests (including tumor markers) and US were carried out. Contrast-enhanced computed tomography (CT) was performed when HCC was suspected, based on US, and/or if the serum α -fetoprotein (AFP) level showed an abnormal increase. HCC was diagnosed by dynamic CT, and hyperattenuation in the arterial phase with washout in the late phase was considered a definite sign of HCC [18]. When a diagnosis of HCC was ambiguous, ultrasound-guided tumor biopsy was